| Name | Title | Contact Details |
|---|
Physician`s Weekly (PW) is a leading source of trusted medical information, perspectives, and education for healthcare providers and patients. As pioneers in delivering medical information at the point of care, Physician`s Weekly supports over 39,000 top medical institutions and group practices across more than 20 specialties. By providing expert medical content through its print and digital products, Physician`s Weekly aims to improve the quality of communication between healthcare providers, their peers, patients, and caregivers.
Lancome USA is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in New York, NY. To find more information about Lancome USA, please visit www.lancome-usa.com
Founded in 1991, AdCare Health Systems, Inc. (NYSE MKT: ADK) is a leading provider of senior living and health care facility management, dedicated to providing the highest quality of healthcare services to the elderly. AdCare operates 46 facilities in Alabama, Arkansas, Georgia, Ohio, Oklahoma, North Carolina, Missouri and South Carolina, with approximately 4,700 beds in service. The facilities comprise 43 skilled nursing centers, three assisted living residences and one senior independent living facility. AdCare owns 24 of the skilled nursing centers and two of the assisted living facilities, with the others operated under long-term lease, consolidated variable interest entity, or management contract.
Linkwell Health is a Needham Heights, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.